The combination of ivosidenib with 5-AzaC further showed a longer event-free survival in IDH1-mutant AML patients relative to patients treated with 5-AzaC and placebo (Montesinos et al., 2022). This evidence concerns the gene IDH1 and acute myeloid leukemia.